Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Phase 2 Trial of Pomalidomide, Ixazomib and Dexamethasone in Patients with Multiple Myeloma with Extramedullary Disease or Plasma Cell Leukemia

Francis K. Buadi, MB, CHB, Martha Q. Lacy, MD, Gabriela Perez, MS, Liang Phuong-Dung, Ankit Kansagra, MD, Thomas E. Witzig, MD, Dania Kaehlyn Helgeson, Karen Woolley, Daniel Auclair, Hearn Jay Cho, MD PhD, Shaji K. Kumar, MD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-142641

Published: 2020

Journal Articles

Identification and Validation of CD138- Multiple Myeloma Immune and Tumor Subpopulations Using Cross Center Scrna-Seq Data

Reyka G Jayasinghe, PhD, Lijun Yao, MS, Beena Thomas, Swati S Bhasin, PhD, Nicolas Fernandez, PhD, David E. Avigan, MD, Taxiarchis Kourelis, MD, Madhav V. Dhodapkar, MD, Ravi Vij, MD MBA, Shaadi Mehr, PhD, Mark Hamilton, PhD, Hearn Jay Cho, MD PhD, Daniel Auclair, Sacha Gnjatic, Li Ding, PhD

Blood (2020) 136 (Supplement 1): 15.

https://doi.org/10.1182/blood-2020-143256

Published: 2020

Journal Articles

Open Label, Multicenter, Dose-Escalation/ Expansion Phase Ib Study to Evaluate Safety and Activity of BET Inhibitor RO6870810 (RO), Given As Monotherapy to Patients (pts) with Advanced Multiple Myeloma

Karthik Ramasamy, Ajay Nooka, MDMPH, Hang Quach, MDFRACP,FRCPA,MBBS, Myo Htut, MD, Rakesh Popat, Michaela Liedtke, MD, Sascha A Tuchman, MD, Jacob P. Laubach, MD, Cristina Gasparetto, MD, Asher A. Chanan-Khan, MD, Mark Hertzberg, MBBS PhDFRACP FRCPA, Mark Demario, MD MPH, Eveline Nueesch, PhD, Evelyne Chesne, PhD, Izolda Franjkovic, PhD, Katharina Lechner, Martin Kornacker, MD, Hearn Jay Cho, MD PhD

Blood (2020) 136 (Supplement 1): 12–14.

https://doi.org/10.1182/blood-2020-136392

Published: 2020

Journal Articles

28-Day Metronomic Therapy for Relapsed Refractory Multiple Myeloma

Tarek H Mouhieddine, MD, Julia Hieulle, Erin Moshier, MS, Josh R. Richter, MD, Hearn Jay Cho, MD PhD, Samir Parekh, MD, Ajai Chari, MD, Bart Barlogie, MD PhD, Sundar Jagannath, MD, Deepu Madduri, MD

Blood (2020) 136 (Supplement 1): 13.

https://doi.org/10.1182/blood-2020-142210

Published: 2020

Journal Articles

Architecture of Sample Preparation and Data Governance of Immuno-Genomic Data Collected from Bone Marrow and Peripheral Blood Samples Obtained from Multiple Myeloma Patients

Shaadi Mehr, PhD, Daniel Auclair, Mark Hamilton, PhD, Leon Rozenblit, Hearn Jay Cho, MD PhD, Lijun Yao, MS, Reyka G Jayasinghe, PhD, Manoj Bhasin, PhD, Steven E. Labkoff, MD, Taxiarchis Kourelis, MD, Madhav V. Dhodapkar, MD, Deon Doxie, Sacha Gnjatic, Cassandra Dewitt, Sergey Miron

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-142882

Published: 2020

Journal Articles

Characterization of Plasma and Immune Cells Molecular Landscape That Play a Role in Rapid Progression of Multiple Myeloma Using Cross Center Scrna-Seq Study

Manoj Bhasin, PhD, Beena E Thomas, Reyka G Jayasinghe, PhD, Nicolas Fernandez, PhD, Swati S Bhasin, PhD, Taxiarchis Kourelis, MD, Madhav V. Dhodapkar, MD, Ravi Vij, Shaji K. Kumar, MD, Shaadi Mehr, PhD, Mark Hamilton, PhD, Hearn Jay Cho, MD PhD, Daniel Auclair, Sacha Gnjatic, Li Ding, PhD, David E. Avigan, MD

Blood (2020) 136 (Supplement 1): 6–8.

https://doi.org/10.1182/blood-2020-143350

Published: 2020

Journal Articles

Effect of Intravenous Immunoglobulin on Infections in Multiple Myeloma (MM) Patients Receiving Daratumumab

Guido Lancman, MD, Dahniel Sastow, BA, Minira Aslanova, MD, Erin Moshier, MS, Hearn Jay Cho, MD PhD, Sundar Jagannath, MD, Deepu Madduri, MD, Samir Parekh, MD, Shambavi Richard, MD, Joshua Richter, MD, Larysa Sanchez, MD, Ajai Chari, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-140056

Published: 2020

Journal Articles

Integrated Cytof, Scrna-Seq and Cite-Seq Analysis of Bone Marrow Immune Microenvironment in the Mmrf Commpass Study

Lijun Yao, MS, Reyka G Jayasinghe, PhD, Beena E Thomas, Swati S Bhasin, PhD, Nicolas Fernandez, PhD, Taxiarchis Kourelis, MD, Deon Doxie, David E. Avigan, MD, Madhav V. Dhodapkar, MD, Shaji K. Kumar, MD, Ravi Vij, MBBS, Shaadi Mehr, PhD, Mark Hamilton, PhD, Hearn Jay Cho, MD PhD, Daniel Auclair, Sacha Gnjatic, PhD, Manoj Bhasin, PhD, Li Ding, PhD

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-142534

Published: 2020

Journal Articles

A Next Generation Liquid Biopsy Approach for Multiple Myeloma

Blood (2020) 136 (Supplement 1): 33.

https://doi.org/10.1182/blood-2020-136865

Published: 2020

Journal Articles

Outcomes in Multiple Myeloma Patients Progressing on Lenalidomide Maintenance

Larysa Sanchez, MD, Erin Moshier, MS, Alexander Coltoff, MD, Ali Mustafa, MD, Darren Pan, MD BS, Hearn Jay Cho, MD PhD, Sundar Jagannath, MD, Deepu Madduri, MD, Samir Parekh, MD, Shambavi Richard, MD, Joshua Richter, MD, Ajai Chari, MD

Blood (2019) 134 (Supplement_1): 1779.

https://doi.org/10.1182/blood-2019-128441

Published: 2019

Journal Articles

Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma

Aparna Raval, PhD, Hearn Jay Cho, MD PhD, Cherie Green, BS, Elisabeth Wassner Fritsch, PharmD, Connie Ma, MS, Naomi Chang, MSc, Mark Yan, PhD, Mark Kockx, MD PhD, Shine Shen, MS, Ling-Yuh Huw, PhD, Emily Balestiere, BA, Marina Lipkind, BS, Huang Huang, MSc, Michelle Byrtek, PhD, Dawn Colburn, PharmD, BCOP, Sandy W. Wong, Jeffrey M. Venstrom, MD PhD, Joanne I Adamkewicz, PhD

Blood (2019) 134 (Supplement_1): 1907.

https://doi.org/10.1182/blood-2019-123652

Published: 2019

Journal Articles

ADAR1 Drives Disease Progression in Multiple Myeloma By Acting Both As an RNA Editor of Specific Transcripts and As a DNA Mutator of Their Cognate Genes

Rafail Nikolaos Tasakis, MSc, BSc, Alessandro Lagana, PhD, Violetta Leshchenko, PhD, David Melnekoff, BS,MS, Itai Beno, PhD, Jonathan J Keats, PhD, Daniel Auclair, Deepu Madduri, MD, Joshua Richter, MD, Ajai Chari, MD, Hearn Jay Cho, MD PhD, Sundar Jagannath, MD, Joel Dudley, PhD, F. Nina Papavasiliou, PhD, Samir Parekh, MD

Blood (2019) 134 (Supplement_1): 3092.

https://doi.org/10.1182/blood-2019-130669

Published: 2019

Journal Articles

Genomic and Immunologic Analysis of Cmaf and Hypermutated Multiple Myeloma: Implications for Immunologic Therapy

Hearn Jay Cho, MD PhD, Deepak Perumal, PhD, Adeeb H Rahman, PhD, Donald Jackson, PhD, Michael Robbins, PhD, Seunghee Kim-Schultze, PhD, Sacha Gnjatic, PhD, Samir Parekh, MD, Jonathan J Keats, PhD, Daniel Auclair

Blood (2019) 134 (Supplement_1): 3093.

https://doi.org/10.1182/blood-2019-131274

Published: 2019

Journal Articles

A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma

Alessandro Lagana, PhD, Sherry Bhalla, Adolfo Aleman, Anna Huo-Chang Mei, MS, Violetta Leshchenko, PhD, Yosef Landesman, PhD, David Melnekoff, BS,MS, Itai Beno, PhD, Deepu Madduri, MD, Joshua R Richter, MD, Ajai Chari, MD, Hearn Jay Cho, MD PhD, Sundar Jagannath, MD, Joel Dudley, PhD, Samir Parekh, MD

Blood (2019) 134 (Supplement_1): 3101.

https://doi.org/10.1182/blood-2019-130753

Published: 2019

Journal Articles

High Dimensional Immune Profiling in Smoldering Multiple Myeloma Identifies Novel Organizing Features of the Tumor Microenvironment

Hearn Jay Cho, MD PhD, Deepak Perumal, PhD, Adeeb H Rahman, PhD, Seunghee Kim-Schultze, PhD, Jennifer Yesil, Daniel Auclair, Tineke Casneuf, PhD, Homer Adams, III, PhD, Samir Parekh, MD, Sacha Gnjatic, PhD, Nicolas Fernandez, PhD

Blood (2019) 134 (Supplement_1): 4384.

https://doi.org/10.1182/blood-2019-130554

Published: 2019

Journal Articles

MAGE-A3 Promotes Chemotherapy Resistance and Proliferation in Multiple Myeloma through Regulation of BIM and p21 Cip1

Hearn Jay Cho, MD, Anna Huo-Chang Mei, MS, Kaity Tung, BS, Jessie Han, Deepak Perumal, PhD, Jonathan J Keats, PhD, Daniel Auclair, PhD, Ajai Chari, MD, Sundar Jagannath, MD, Samir Parekh, MD, Alessandro Lagana, PhD

Blood (2018) 132 (Supplement 1): 4464.

https://doi.org/10.1182/blood-2018-99-118692

Published: 2018

Journal Articles

Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma

Blood (2018) 132 (Supplement 1): 59.

https://doi.org/10.1182/blood-2018-99-116828

Published: 2018

Journal Articles

Mechanisms of CD4 T Cell Tumor Immunity in a Preclinical Model of Multiple Myeloma

Selma Bekri, PhD, Reunet Rodney-Sandy, BS, Diana Gruenstein, BS, Bjarne Bogen, MD PhD, Daniel Levey, PhD, Hearn Jay Cho, MD

Blood (2018) 132 (Supplement 1): 1947.

https://doi.org/10.1182/blood-2018-99-117129

Published: 2018

Journal Articles

Atezolizumab in Combination with Daratumumab with or without Lenalidomide or Pomalidomide: A Phase Ib Study in Patients with Multiple Myeloma

Hearn Jay Cho, MD, Luciano J Costa, MD PhD, Faith E. Davies, MD, Natalia Neparidze, MD, Ravi Vij, Yuning Feng, Anastasia Teterina, Elisabeth Wassner Fritsch, Michael Wenger, Jonathan L Kaufman, MD

Blood (2018) 132 (Supplement 1): 597.

https://doi.org/10.1182/blood-2018-99-114960

Published: 2018

Journal Articles

E2F1 Is a Biomarker of Selinexor Resistance in Relapsed/Refractory Multiple Myeloma Patients

Alessandro Lagana, PhD, Seongjee Park, Donna Edwards, Violetta Leshchenko, PhD, Marsha Crochiere, Yosef Landesman, PhD, David Melnekoff, BS,MS, Itai Beno, PhD, Deepak Perumal, PhD, Deepu Madduri, MD, Joshua Richter, Ajai Chari, MD, Hearn Jay Cho, MD, Bart Barlogie, MD PhD, Sundar Jagannath, MD, Joel Dudley, PhD, Samir Parekh, MD

Blood (2018) 132 (Supplement 1): 3216.

https://doi.org/10.1182/blood-2018-99-116500

Published: 2018

NARROW

Phase 2 Trial of Pomalidomide, Ixazomib and Dexamethasone in Patients with Multiple Myeloma with Extramedullary Disease or Plasma Cell Leukemia

Identification and Validation of CD138- Multiple Myeloma Immune and Tumor Subpopulations Using Cross Center Scrna-Seq Data

Open Label, Multicenter, Dose-Escalation/ Expansion Phase Ib Study to Evaluate Safety and Activity of BET Inhibitor RO6870810 (RO), Given As Monotherapy to Patients (pts) with Advanced Multiple Myeloma

28-Day Metronomic Therapy for Relapsed Refractory Multiple Myeloma

Architecture of Sample Preparation and Data Governance of Immuno-Genomic Data Collected from Bone Marrow and Peripheral Blood Samples Obtained from Multiple Myeloma Patients

Characterization of Plasma and Immune Cells Molecular Landscape That Play a Role in Rapid Progression of Multiple Myeloma Using Cross Center Scrna-Seq Study

Effect of Intravenous Immunoglobulin on Infections in Multiple Myeloma (MM) Patients Receiving Daratumumab

Integrated Cytof, Scrna-Seq and Cite-Seq Analysis of Bone Marrow Immune Microenvironment in the Mmrf Commpass Study

A Next Generation Liquid Biopsy Approach for Multiple Myeloma

Outcomes in Multiple Myeloma Patients Progressing on Lenalidomide Maintenance

Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma

ADAR1 Drives Disease Progression in Multiple Myeloma By Acting Both As an RNA Editor of Specific Transcripts and As a DNA Mutator of Their Cognate Genes

Genomic and Immunologic Analysis of Cmaf and Hypermutated Multiple Myeloma: Implications for Immunologic Therapy

A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma

High Dimensional Immune Profiling in Smoldering Multiple Myeloma Identifies Novel Organizing Features of the Tumor Microenvironment

MAGE-A3 Promotes Chemotherapy Resistance and Proliferation in Multiple Myeloma through Regulation of BIM and p21 Cip1

Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma

Mechanisms of CD4 T Cell Tumor Immunity in a Preclinical Model of Multiple Myeloma

Atezolizumab in Combination with Daratumumab with or without Lenalidomide or Pomalidomide: A Phase Ib Study in Patients with Multiple Myeloma

E2F1 Is a Biomarker of Selinexor Resistance in Relapsed/Refractory Multiple Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only